Skip to main content
Premium Trial:

Request an Annual Quote

Igenbio, Genome Compiler Team to Create Synthetic Bio Solutions

NEW YORK (GenomeWeb) – Genome analysis firm Igenbio said today it has struck a collaborative agreement with the synthetic biology software design firm Genome Compiler to develop new solutions targeting the synthetic biology community.

The partners will use Chicago-based Igenbio's ERGO genome and analysis discovery system and Genome Compiler's proprietary biology designs solution. ERGO is a web-based platform that integrates functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with other information in the public sphere.

Genome Compiler, based in Los Angeles, provides a software platform for bio-engineering and genomic manipulation tools.

"Partnering with Genome Compiler to create a single integrated platform providing exceptional annotations, pathways, and an enormous curated parts database across all genomes will enable scientists to expedite new product creation," Igenbio's President and CEO Vinayak Kapatral said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.